Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FATE Fate Therapeutics

Closed 12-18 16:00:00 EST

1.69

-0.19

-10.37%

盘后1.73

+0.04+2.67%

19:31 EST

High1.88	Low1.64	Vol4.62M
Open1.87	D1 Closing1.88	Amplitude12.77%
Mkt Cap191.91M	Tradable Cap166.46M	Total Shares113.89M
T/O7.99M	T/O Rate4.67%	Tradable Shares98.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics","latestPrice":1.685,"timestamp":1734555600000,"preClose":1.88,"halted":0,"volume":4616785,"hourTrading":{"tag":"盘后","latestPrice":1.73,"preClose":1.685,"latestTime":"19:31 EST","volume":22785,"amount":39334.0239,"timestamp":1734568314051},"delay":0,"floatShares":98789051,"shares":113894333,"eps":-1.641185,"marketStatus":"Closed","change":-0.195,"latestTime":"12-18 16:00:00 EST","open":1.87,"high":1.88,"low":1.64,"amount":7992857.045814,"amplitude":0.12766,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.641185,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734598800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":1.88,"preHourTrading":{"tag":"盘前","latestPrice":1.89,"preClose":1.88,"latestTime":"09:29 EST","volume":4497,"amount":8514.7497633,"timestamp":1734532171680},"postHourTrading":{"tag":"盘后","latestPrice":1.73,"preClose":1.685,"latestTime":"19:31 EST","volume":22785,"amount":39334.0239,"timestamp":1734568314051},"volumeRatio":1.234067,"impliedVol":0.5638,"impliedVolPercentile":0.131},"requestUrl":"/m/hq/s/FATE","defaultTab":"news","newsList":[{"id":"2491332245","title":"Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?","url":"https://stock-news.laohu8.com/highlight/detail?id=2491332245","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491332245?lang=en_us&edition=fundamental","pubTime":"2024-12-13 00:30","pubTimestamp":1734021026,"startTime":"0","endTime":"0","summary":"It has been about a month since the last earnings report for Fate Therapeutics . Shares have added about 0.5% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Fate Therapeutics due for a pullback?Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.Q3 Earnings Beat on Higher Revenues, Pipeline in Focus. Fate Therapeutics reported a loss of 40 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 42 cents.The company reported a loss of 46 cents per share in the year-ago period.Fate also amended the clinical protocol of its phase I autoimmunity study on FT819 to include a second treatment arm  to assess the safety, pharmacokinetics, and anti-B cell activity of a single dose of FT819 as an add-on to maintenance therapy wit","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QOfludHza1dTKV8R6Coeiw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QOfludHza1dTKV8R6Coeiw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-fate-0-5-163026291.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLDX","FATE"],"gpt_icon":0},{"id":"2490836961","title":"Barclays Gives a Buy Rating to Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2490836961","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490836961?lang=en_us&edition=fundamental","pubTime":"2024-12-11 17:25","pubTimestamp":1733909110,"startTime":"0","endTime":"0","summary":"In a report released today, Peter Lawson from Barclays assigned a Buy rating to Fate Therapeutics (FATE – Research Report), with a price target of ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-gives-a-buy-rating-to-fate-therapeutics-fate?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-gives-a-buy-rating-to-fate-therapeutics-fate?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE"],"gpt_icon":0},{"id":"2490928067","title":"Hold Rating for Fate Therapeutics Amid Incremental Progress in CD19 CAR-T Therapy Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2490928067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490928067?lang=en_us&edition=fundamental","pubTime":"2024-12-10 17:45","pubTimestamp":1733823954,"startTime":"0","endTime":"0","summary":"Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Hold rating on Fate Therapeutics (FATE – Research Report). The associated ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/hold-rating-for-fate-therapeutics-amid-incremental-progress-in-cd19-car-t-therapy-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/hold-rating-for-fate-therapeutics-amid-incremental-progress-in-cd19-car-t-therapy-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","PRGS","CAR"],"gpt_icon":0},{"id":"2490812540","title":"Fate Therapeutics Reports FT819 Shows 'Favorable Safety Profile,' Clinical Benefits","url":"https://stock-news.laohu8.com/highlight/detail?id=2490812540","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490812540?lang=en_us&edition=fundamental","pubTime":"2024-12-10 06:41","pubTimestamp":1733784101,"startTime":"0","endTime":"0","summary":"Fate Therapeutics  said new data from FT819's phase 1 study in patients with moderate to severe systemic lupus erythematosus showed no dose-limiting toxicities in the first three patients.The drug showed rapid, deep and sustained depletion of CD19+ B cells in the periphery and a \"favorable safety profile,\" the company said Monday in a statement.One patient reaching six-month follow-up achieved clinical remission and remains free of immunosuppressive therapy, the company said.Shares of the company rose 1.5% in recent after-hours activity.Price: 2.7598, Change: +0.04, Percent Change: +1.46","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","FATE"],"gpt_icon":0},{"id":"2490012083","title":"BRIEF-Fate Therapeutics Presents New Phase 1 Clinical Data Of Ft819 Off-The-Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2490012083","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490012083?lang=en_us&edition=fundamental","pubTime":"2024-12-10 05:27","pubTimestamp":1733779650,"startTime":"0","endTime":"0","summary":"Dec 9 (Reuters) - Fate Therapeutics Inc   :   * FATE THERAPEUTICS PRESENTS NEW PHASE 1 CLINICAL DATA OF FT819 OFF-THE-SHELF, CAR T-CELL PRODUCT CANDIDATE FOR SYSTEMIC LUPUS ERYTHEMATOSUSSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"gpt_icon":0},{"id":"2490088991","title":"Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 off-the-Shelf, Car T-Cell Product Candidate for Systemic Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=2490088991","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490088991?lang=en_us&edition=fundamental","pubTime":"2024-12-10 05:01","pubTimestamp":1733778094,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nFWN3NA1FP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"gpt_icon":0},{"id":"2490884580","title":"Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=2490884580","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490884580?lang=en_us&edition=fundamental","pubTime":"2024-12-10 05:01","pubTimestamp":1733778060,"startTime":"0","endTime":"0","summary":"All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2994080/24675/en/Fate-Therapeutics-Presents-New-Phase-1-Clinical-Data-of-FT819-Off-the-shelf-CAR-T-cell-Product-Candidate-for-Systemic-Lupus-Erythematosus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","WRD","CRS","BK4109","FATE","IE00B19Z4B17.USD","IE00B66KJ199.SGD","SLE","BK4230","CAR","BK4139","BK4006","IE0031619046.USD","ASH","IE00B7SZL793.SGD","BK4077","BK4022","PHH"],"gpt_icon":0},{"id":"2489284126","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Veeva Systems (VEEV) and Alcon (ALC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489284126","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489284126?lang=en_us&edition=fundamental","pubTime":"2024-12-06 20:31","pubTimestamp":1733488271,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fate Therapeutics (FATE – Research Report), Veeva Systems (VEEV –...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-fate-therapeutics-fate-veeva-systems-veev-and-alcon-alc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-fate-therapeutics-fate-veeva-systems-veev-and-alcon-alc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1804176565.USD","BK4137","LU0266013472.USD","FATE","BK4198","LU0058720904.USD","LU1989764748.USD","HCSG","LU2265009873.SGD","ALC","BK4534","BK4588","BK4528","BK4504","LU1989764664.SGD","BK4167","BK4139","VEEV","BK4585","LU0289739699.SGD"],"gpt_icon":0},{"id":"2488976306","title":"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2488976306","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488976306?lang=en_us&edition=fundamental","pubTime":"2024-12-04 05:01","pubTimestamp":1733259660,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Dec.  03, 2024  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/03/2991037/24675/en/Fate-Therapeutics-Reports-New-Employee-Inducement-Award-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","LU2210150020.SGD","FATE","BK4585","LU2095319765.USD","WRD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4139","IE00BKPKM429.USD","BK4588","BK4112",".IXIC"],"gpt_icon":0},{"id":"2487919475","title":"Fate Therapeutics Announces Leadership Transition for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2487919475","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487919475?lang=en_us&edition=fundamental","pubTime":"2024-11-30 03:58","pubTimestamp":1732910296,"startTime":"0","endTime":"0","summary":"An update from Fate Therapeutics ( ($FATE) ) is now available. Fate Therapeutics announces a leadership change as Scott Wolchko steps down as CEO, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-announces-leadership-transition-for-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-announces-leadership-transition-for-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"gpt_icon":0},{"id":"2487953235","title":"Fate Therapeutics Taps Bob Valamehr to Be CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2487953235","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487953235?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:38","pubTimestamp":1732905480,"startTime":"0","endTime":"0","summary":"Fate Therapeutics has appointed Bob Valamehr to succeed Scott Wolchko as chief executive, effective a Jan. 1.The clinical-stage biopharmaceutical company on Friday said that Valamehr has headed the development of its induced pluripotent stem cell platform, and led to 13 investigational new drug applications, covering the treatment of hematological malignancies, solid tumors and autoimmune disorders.He is set to take over the day after Wolchko's effective retirement date of Dec. 31. Wolchko has led the San Diego-based company since 2015, and will continue to act as a strategic adviser to the company, Fate Therapeutics said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"gpt_icon":0},{"id":"2487938205","title":"BRIEF-Fate Therapeutics Says Bob Valamehr To Become President, CEO As Of Jan 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2487938205","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487938205?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:16","pubTimestamp":1732904204,"startTime":"0","endTime":"0","summary":"BRIEF-Fate Therapeutics Says Bob Valamehr To Become President, CEO As Of Jan 2025Nov 29 (Reuters) - Fate Therapeutics Inc FATE.O:FATE THERAPEUTICS ANNOUNCES LEADERSHIP TRANSITIONFATE THERAPEUTICS INC ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nTUA4CHXDY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FATE"],"gpt_icon":0},{"id":"2487593591","title":"Fate Therapeutics CEO Wolchko to retire","url":"https://stock-news.laohu8.com/highlight/detail?id=2487593591","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487593591?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:10","pubTimestamp":1732903830,"startTime":"0","endTime":"0","summary":"Fate Therapeutics (FATE), announced that Scott Wolchko, the company’s President and CEO, will retire effective December 31, 2024. Fate’s current Pr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-ceo-wolchko-to-retire?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-ceo-wolchko-to-retire?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"gpt_icon":0},{"id":"2487659814","title":"Fate Therapeutics Inc - Scott Wolchko to Continue as Strategic Advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2487659814","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487659814?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:05","pubTimestamp":1732903502,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nTUA4CHXDY:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"gpt_icon":0},{"id":"2487598149","title":"Fate Therapeutics Inc - Bob Valamehr to Become President and CEO Jan 1, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2487598149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487598149?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:05","pubTimestamp":1732903502,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nTUA4CHXDY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"gpt_icon":0},{"id":"2487598143","title":"Fate Therapeutics Announces Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2487598143","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487598143?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:05","pubTimestamp":1732903502,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nTUA4CHXDY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"gpt_icon":0},{"id":"2487110598","title":"Press Release: Fate Therapeutics Announces Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2487110598","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487110598?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:05","pubTimestamp":1732903500,"startTime":"0","endTime":"0","summary":"Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025. Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies. SAN DIEGO, Nov. 29, 2024  -- Fate Therapeutics, Inc.  , a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell -derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Scott Wolchko, the Company's President and CEO, will retire effective December 31, 2024. Fate's current President of Research and Development (R&D), Bob Valamehr, Ph.D. MBA, will assume the role of President and CEO as of January 1, 2025. Fate Therapeutics will passionately continue its mission to develop novel off-the-shelf cellular immunotherapies to broadly treat patients in need.Included in the Company's product candidate pipeline is FT819, the Company's off-the-shelf, CD19-targeted, 1XX CAR T-cell","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WRD","BK4077","FATE","BK4139","SLE"],"gpt_icon":0},{"id":"2486831103","title":"Fate Therapeutics to Present at Upcoming December Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2486831103","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486831103?lang=en_us&edition=fundamental","pubTime":"2024-11-27 05:01","pubTimestamp":1732654860,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov.  26, 2024  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/26/2987804/24675/en/Fate-Therapeutics-to-Present-at-Upcoming-December-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","WRD","FATE"],"gpt_icon":0},{"id":"2485081439","title":"Positive Clinical Developments and Promising Outcomes Propel Fate Therapeutics’ Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2485081439","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485081439?lang=en_us&edition=fundamental","pubTime":"2024-11-21 14:18","pubTimestamp":1732169883,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Daina Graybosch has maintained their bullish stance on FATE stock, giving a Buy rating on November 19. Daina Graybosch has...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-clinical-developments-and-promising-outcomes-propel-fate-therapeutics-growth-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-clinical-developments-and-promising-outcomes-propel-fate-therapeutics-growth-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"gpt_icon":0},{"id":"2485644176","title":"Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2485644176","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485644176?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:34","pubTimestamp":1732138456,"startTime":"0","endTime":"0","summary":"Fate Therapeutics, Inc. reported positive phase 1 data for FT819 in treating moderate-to-severe Systemic Lupus Erythematosus, showing remission in one patient with fludarabine-free conditioning.A seco","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1096502340/image_1096502340.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1096502340/image_1096502340.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4739123-fate-therapeutics-ft819-finding-bodes-well-for-future-of-sle-treatment-options","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","FATE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1754},{"period":"1month","weight":-0.0693},{"period":"3month","weight":-0.5155},{"period":"6month","weight":-0.4763},{"period":"1year","weight":-0.4032},{"period":"ytd","weight":-0.4973}],"compareEarnings":[{"period":"1week","weight":0.0025},{"period":"1month","weight":0.0317},{"period":"3month","weight":0.0764},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.2804},{"period":"ytd","weight":0.2714}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.058546},{"month":2,"riseRate":0.636364,"avgChangeRate":0.08272},{"month":3,"riseRate":0.545455,"avgChangeRate":0.019657},{"month":4,"riseRate":0.545455,"avgChangeRate":-0.055265},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.016902},{"month":6,"riseRate":0.545455,"avgChangeRate":0.010259},{"month":7,"riseRate":0.454545,"avgChangeRate":0.056385},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.021881},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.018445},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.106424},{"month":11,"riseRate":0.583333,"avgChangeRate":0.111361},{"month":12,"riseRate":0.583333,"avgChangeRate":0.066351}],"exchange":"NASDAQ","name":"Fate Therapeutics","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fate Therapeutics,FATE,Fate Therapeutics股票,Fate Therapeutics股票老虎,Fate Therapeutics股票老虎国际,Fate Therapeutics行情,Fate Therapeutics股票行情,Fate Therapeutics股价,Fate Therapeutics股市,Fate Therapeutics股票价格,Fate Therapeutics股票交易,Fate Therapeutics股票购买,Fate Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction